AKT1S1 (AKT1 Substrate 1)

Pharmacological inhibition of acetylation attenuated PRAS40-mediated CRC stemness and colorectal carcinogenesis. Collectively, our findings uncover a novel PRAS40/PGK1 regulatory axis that promotes CRC stemness and tumorigenesis through enhanced glycolysis, suggesting potential therapeutic strategies targeting this axis for CRC treatment.

PRAS40 is strongly associated with primary ICB resistance in NSCLC and may serve as a novel predictive biomarker. These findings support its potential to guide personalized immunotherapy in lung cancer.

EPA in the presence of TMZ reduced the phosphorylation of GSK3α/β, Akt 1/2/3, HSP27, and WNK1, while DHA reduced the phosphorylation of ERK 1/2, GSK3α/β, AMPKα1, Akt 1/2/3, and WNK1, thereby leading to additive or synergistic effects of EPA or DHA in combination with TMZ. Overall, the present study highlights the alterations seen in TMZ-resistant glioma cells when exposed to EPA or DHA and demonstrates the therapeutic potential that modulation of lipid metabolism can exert upon important aspects of glioma cell biology.

Molecular docking results demonstrated that these active compounds exhibited strong binding affinities with key target proteins such as PI3K and JAK1 (binding energy < -5.0 kcal/mol). This study elucidates the multi-target, multi-pathway synergistic mechanisms by which dandelion extract inhibits breast cancer, providing a theoretical basis for the development of novel antitumor agents.

We suggest that mTOR inhibition is a potential treatment of choice for canine prostate cancer, which may guide and contribute to future prostate carcinoma clinical trials. However, the acquisition of resistance to treatment remains a challenge, and precision medicine may help overcome this problem.

In alpelisib-treated GC cells with PIK3CA mutations, PTEN functional loss and changes in the associated signaling pathway were identified as important mechanisms of acquired alpelisib resistance. The combination of capivasertib and SN38 effectively overcomes acquired resistance to alpelisib in PIK3CA-mutant GC, providing a preclinical rationale for future clinical trials targeting acquired alpelisib-resistant GC with PIK3CA mutations.

Empagliflozin reduces prostate cancer cell viability and enhances the cytotoxic effects of docetaxel, suggesting a promising combination strategy for prostate cancer therapy. Additional in vivo studies and clinical trials are needed to assess the translational relevance of these findings.

HIP1R is a new gene implicated in RA FLS invasiveness and migration, and regulates unique pathways and cell processes relevant to both RA as well as cancer biology. Our study provides new insight into processes implicated in FLS invasiveness, which is relevant for joint damage in RA, and identify new potential gene targets for FLS-specific treatments.

Fluoxetine demonstrates promising anti-tumor activity in OSCC by inducing apoptosis, inhibiting metastasis, and targeting oncogenic signaling pathways. These findings suggest that fluoxetine may serve as a potential therapeutic agent for OSCC, warranting further investigation for clinical application.

P1, N=25, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2025 --> Feb 2026

Furthermore, L1Cu(NO2) induced cell apoptosis and upregulated the expression of p-PRAS40 (proline-rich Akt substrate of 40 kDa) in oral cancer cells. All these results reveal the therapeutic potential of copper-nitrite complexes, especially L1Cu(NO2), to be developed as a targeted therapy against oral precancer and cancer.

P1, N=24, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting